FSS Vs. Samsung BioLogics - Latest Situation Update
Below is how the Samsung BioLogics accounting fraud case will be reviewed and concluded by the FSC. The FSS (Financial Supervisory Service) tables...
328 Views
Genoray IPO Preview (Part 2) - Valuation Analysis
We are positive on the Genoray IPO. Our one year price target of the company is 25,944 won, which would represent nearly 27% higher than the high...
325 Views
Samsung BioLogics - Market Sentiment Assessment
The Samsung Biologics Co., Ltd (207940 KS) accounting fraud claim news came out on May 1 (Korea's labor day - statutory holiday). The next three...
287 Views
Samsung BioLogics and Biogen: Who Had Control?
The controversy surrounding Samsung Biologics Co., Ltd (207940 KS) 's booking of a fair value gain in 2015 relates to their claim of a "loss of...
473 Views
Samsung Biologics' Accounting Violation's Impact on Samsung C&T and Rest of the Korean Pharmas
On May 1st, 2018, Korea's Financial Supervisory Service (FSS) announced that Samsung Biologics Co., Ltd (207940 KS) violated accounting rules after...
309 Views